- Veterinary medicines, comprising pharmaceuticals and biologics used for animal treatment and disease prevention, are increasingly vital components of China’s rapidly evolving animal health ecosystem due to their role in ensuring livestock productivity, food safety, and pet wellness
- The escalating demand for veterinary medicines in China is primarily fueled by the rising prevalence of zoonotic diseases, expanding livestock population, and the increasing awareness among pet owners about animal health and welfare
- China dominated the Asia-pacific veterinary medicine market with the largest revenue share of 41.7% in 2024, driven by government initiatives promoting livestock disease control, growing pet adoption in urban areas, and rising investments in veterinary research and infrastructure development
- The country’s veterinary sector is also supported by robust pharmaceutical manufacturing capabilities and a surge in demand for veterinary vaccines and antiparasitic drugs due to the increasing focus on preventing disease outbreaks in both livestock and companion animals
- The production animals segment dominated the China veterinary medicine market with a market share of 62.3% in 2024, due to the high demand for veterinary medicines in livestock sectors such as poultry, cattle, and swine farming. The segment’s growth is primarily driven by the rising consumption of meat, milk, and other animal products in China, combined with government support for animal health
